Feb 12 (Reuters) - Kamada Ltd KMDA.TA :
* KAMADA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND
FISCAL
YEAR 2018
* Q4 EARNINGS PER SHARE $0.44
* Q4 REVENUE ROSE 35 PERCENT TO $48.2 MILLION
* SEES FY 2019 REVENUE $125 MILLION TO $130 MILLION
* REITERATING FULL-YEAR 2019 TOTAL REVENUE GUIDANCE OF $125
MILLION TO $130 MILLION
* PENDING FDA CLEARANCE OF REQUESTED INFORMATION, CO INTENDS
TO
INITIATE A PHASE 3 CLINICAL TRIAL OF INHALED AAT DURING 2019
* TOP-LINE DATA FROM PHASE 2 TRIAL OF IV-AAT IS EXPECTED BY
END OF
2019
Source text for Eikon: ID:nGNX5K8Ms2
Further company coverage: KMDA.TA
((Reuters.Briefs@thomsonreuters.com;))